Research programme: respiratory disorder therapeutics - AzarGen Biotechnologies

Drug Profile

Research programme: respiratory disorder therapeutics - AzarGen Biotechnologies

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AzarGen Biotechnologies
  • Class Plant proteins; Pulmonary surfactant associated proteins
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Neonatal respiratory distress syndrome

Most Recent Events

  • 25 Jul 2017 AzarGen Biotechnologies has patent protection for method of production of human pulmonary surfactant protein-B in Europe
  • 29 Sep 2016 AzarGen Biotechnologies and iBio Inc. enter into a commercial developemnt agreement for surfactant proteins for Neonatal respiratory distress syndrome before September 2016
  • 29 Sep 2016 Early research in Neonatal respiratory distress syndrome in South Africa (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top